Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 674-682

  Nakajima, Miki ^a   Fujiki, Yuto ^a   Kyo, Satoru ^a   Kanaya, Taro ^a   Nakamura, Mitsuhiro ^a   Maida, Yoshiko ^a   Tanaka, Masaaki ^a   Inoue, Masaki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Genetic polymorphism; P glycoprotein; Pharmacokinetics

Indexed keywords

3' 4 HYDROXYPACLITAXEL; 6ALPHA HYDROXYPACLITAXEL; CARBOPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER TOXICITY; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; OVARY CANCER; THROMBOCYTOPENIA;

AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENES, MDR; HUMANS; INDIVIDUALITY; INFUSIONS, INTRAVENOUS; JAPAN; LEUKOPENIA; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; OVARIAN NEOPLASMS; PACLITAXEL; POLYMORPHISM, GENETIC; THROMBOCYTOPENIA; VOMITING;

EID: 18844361872     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005276204     Document Type: Article

References (34)

1. Horwitz SB, Lothstein L, Manfredi JJ, et al. Taxol: mechanisms of action and resistance. Ann N Y Acad Sci. 1986;466:433-444.
2. Monsarrat B, Alvinerie P, Wright M, et al. Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr. 1993;15:39-46.
3. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543-5546.
4. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of Taxol. J Med Chem. 1994;37:706-709.
5. Sparreboom A, Huizing MT, Boesen JJB, Nooijen WJ, van Tellingen O, Beijnen JH. Isolation, purification and biological activity of monoand dihydroxylated paclitaxel (Taxol) metabolites from human faeces. Cancer Chemother Pharmacol. 1995;36:299-304.
6. Kumar G, Ray S, Walle T, et al. Comparative in vitro cytotoxic effects of Taxol and its major human metabolite 6α-hydroxytaxol. Cancer Chemother Pharmacol. 1995;36:129-135.
7. Harris JW, Kim BR, Guengerich FP, Collins JM. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome p450 3A4 and an unknown P450 enzyme. Cancer Res. 1994;54:4026-4035.
8. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994;54:386-392.
9. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94:2031-2035.
10. van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer. 1997;76:1181-1183.
11. Wu H, Hait WN, Yang J-M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515-1519.
12. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93:98-106.
13. Daly AK. Pharmacogenetics. In: Woolf TF, ed. Handbook of Drug Metabolism. New York, NY: Marcel Dekker; 1999:175-202.
14. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285-307.
15. Willey TA, Bekos EJ, Gaver RC, Dunca GF, Tay LK. High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma. J Chromatogr. 1993;621:231-238.
16. Nakajima M, Fujiki Y, Noda K, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos. 2003;31:687-690.
17. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268-273.
18. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12:121-132.
19. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-1143.
20. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-174.
21. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
22. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597-607.
23. Bahadur N, Leathart JBS, Mutch E, et al. CYP2C8 polymorphisms in Caucasian and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64:1579-1589.
24. Soyama A, Saito Y, Hanioka N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull. 2001;24:1427-1430.
25. Soyama A, Saito Y, Komamura K, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet. 2002;17:374-377.
26. Dai D, Yang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825-831.
27. Murayama N, Nakamura T, Saeki M, et al. CYP3A4 gene polymorphisms influence testosterone 6β-hydroxylation. Drug Metab Pharmacokinet. 2002;17:150-156.
28. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:676-684.
29. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15:317-329.
30. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res. 1996;2:549-552.
31. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos. 1995;23:506-512.
32. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol. 1995; 13:180-190.
33. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1, MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11:175-184.
34. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97:3473-3478.